Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

The uptake of subcutaneous rituximab has lagged behind the use of the intravenous version in non-Hodgkin lymphoma.

Subcutaneous Rituximab Remains Underutilized in Non-Hodgkin Lymphoma

John Seymour, MBBS, FRACP, PhD, discusses the role of genetic profiling in the treatment of chronic lymphocytic leukemia. 

Dr Seymour on the Role of Mutational Profiling in CLL

Liso-cel produced responses across subgroups of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features

Treatment with valemetostat demonstrated activity and was tolerable in patients with relapsed/refractory peripheral T-cell lymphoma.

Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Articles

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

D-VRd improved rates of MRD negativity and sustained MRD negativity vs VRd in transplant-eligible, newly diagnosed multiple myeloma.

D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

The Evolving Treatment Landscape in Light Chain Amyloidosis with Cardiac Involvement

Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial

Videos

Expert oncologists discuss the current treatment landscape and latest data in the treatment of patients with AL amyloidosis with cardiac involvement.

Expert oncologists Dr. Jeffrey Zonder and Dr. Shaji Kumar discuss AL amyloidosis background, typical patient profiles, and disease staging and risk stratification.

AL Amyloidosis: Background, Patient Profile, and Staging

Dr. Kumar discusses best practices for accurately and prompt diagnosing AL amyloidosis as well as navigating differential diagnosis.

Navigating the Differential Diagnosis of AL Amyloidosis

Dr. Zonder discusses the current treatment landscape in AL amyloidosis, highlighting recent advances.

Treatment Approaches in AL Amyloidosis 

Expert oncologist Dr. Kumar provides his assessment of unmet needs in AL Amyloidosis, particularly patients with cardiac involvement.

Limitations of Available Treatment Options for Patients with Cardiac Involvement 

Drs. Kumar and Zonder discuss results from the Phase III Vital trial investigating birtamimab and key takeaways.

Dr. Zonder discusses the safety profile of birtamimab in the VITAL study and the clinical implications.

Birtamimab Safety Profile in the VITAL Study

Dr. Kumar discusses strategies for managing adverse events in patients with AL amyloidosis.

Adverse Event Management in AL Amyloidosis

Dr. Kumar and Dr. Zonder discuss the ongoing confirmatory Phase III AFFIRM-AL trial investigating the efficacy and safety of birtamimab and ongoing recruitment in the trial.

Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment

Expert oncologists discuss the progression treatment landscape in AL amyloidosis and agents of investigation.

Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches

Dr. Zonder and Dr. Kumar share their clinical pearls and perspectives on future directions in the treatment of AL amyloidosis.

Clinical Pearls and Future Directions in AL Amyloidosis

Insights Video Series

Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial

EP: 1.AL Amyloidosis: Background, Patient Profile, and Staging

EP: 2.Navigating the Differential Diagnosis of AL Amyloidosis

EP: 3.Treatment Approaches in AL Amyloidosis

EP: 4.Limitations of Available Treatment Options for Patients with Cardiac Involvement

EP: 5.Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial

EP: 6.Birtamimab Safety Profile in the VITAL Study

EP: 7.Adverse Event Management in AL Amyloidosis

EP: 8.Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment

EP: 9.Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches

EP: 10.Clinical Pearls and Future Directions in AL Amyloidosis

Latest Conference Coverage